EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review

Xiangwei Meng, Chunqing Che, Yingjie Yi, Xiaoyang Qu

Frontiers in Bioengineering and Biotechnology · 22.07.2025 · 13

DOI: 10.3389/fbioe.2025.1635747 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 22.07.2025. Verfasst von Xiangwei Meng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanomaterial-induced immunogenic cell death (ICD) represents a transformative approach to overcoming limitations of conventional cancer immunotherapies. Unlike traditional methods hindered by systemic toxicity and inadequate targeting, nanomaterials precisely deliver therapeutic agents and effectively modulate tumor microenvironmental factors, including hypoxia, acidity, and redox imbalance. By triggering ICD through mechanisms such as reactive oxygen species generation, tumor acidity neutralization, and hypoxia alleviation, nanomaterials facilitate potent anti-tumor immune responses, enhance dendritic cell activation, and promote cytotoxic T lymphocyte recruitment. Additionally, integrating nanomaterial-induced ICD with established immunotherapies like checkpoint inhibitors and CAR-T cells has shown promising preclinical synergy, enabling robust and lasting antitumor immunity. Despite significant translational challenges related to safety, standardization, and tumor heterogeneity, continued advances in multifunctional nanoplatform development and personalized therapeutic strategies hold substantial promise for improving cancer treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

cancer immunotherapyimmunogenic cell death (ICD)nanomaterialstargeted drug deliverytumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China.
  • Department of Drug Clinical Trials, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, China.
  • Department of West Hospital Orthopaedic Trauma, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, China.
  • Department of Pediatrics, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, China.
  • Department of Infectious Diseases, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, China.

Zitieren

APA

Meng, X., Che, C., Yi, Y., & Qu, X. (2025). Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review. Frontiers in Bioengineering and Biotechnology, 13. https://doi.org/10.3389/fbioe.2025.1635747

Vancouver

Meng X, Che C, Yi Y, Qu X. Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review. Frontiers in Bioengineering and Biotechnology. 2025;13. doi:10.3389/fbioe.2025.1635747

BibTeX
@article{Meng2025,
  author = {Meng, Xiangwei and Che, Chunqing and Yi, Yingjie and Qu, Xiaoyang},
  title = {Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review},
  journal = {Frontiers in Bioengineering and Biotechnology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fbioe.2025.1635747}
}
Kostenlos starten →